LIFYORLI™ (relacorilant)
March 25, 2026
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
Louisville, KY — March 25, 2026 — Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as the national specialty pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.1
“We are extremely excited to announce our partnership with Corcept Therapeutics as the sole authorized national specialty pharmacy for LIFYORLI, which reflects the growing need for accessible, well-supported treatment options in rare and complex oncology care,” said Benito Fernandez, Chief Commercial Officer. “Onco360 is focused on simplifying the path to therapy while delivering high-touch, clinical support for patients and their caregivers.”
LIFYORLI (relacorilant) is the first U.S. Food and Drug Administration (FDA)-approved selective glucocorticoid receptor antagonist (SGRA) for adults with platinum-resistant ovarian cancer. It is an oral medication taken the day before, the day of, and the day after treatment with nab-paclitaxel. There is no biomarker requirement for LIFYORLI. LIFYORLI competitively binds to the glucocorticoid receptor (GR), where it enhances chemotherapy sensitivity by inhibiting cortisol’s suppression of apoptosis – the programmed cell death that chemotherapies such as nab-paclitaxel are meant to cause. LIFYORLI does not have any effect on the body’s other steroid receptors.
LIFYORLI’s approval was based on the pivotal phase 3 ROSELLA study, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, at least one of which included bevacizumab.2 Patients were randomized 1:1 to receive either LIFYORLI plus nab-paclitaxel or nab-paclitaxel monotherapy. The ROSELLA study met its dual primary endpoints of progression-free and overall survival. Patients treated with LIFYORLI in addition to nab-paclitaxel experienced a 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.65; p-value: 0.0004), with a median overall survival (OS) of 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone, a difference of 4.1 months. Patients who received LIFYORLI in addition to nab-paclitaxel also experienced a 30 percent reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008), as assessed by blinded independent central review (PFS-BICR), compared to patients treated with nab-paclitaxel alone. The most common (>20%) adverse reactions include laboratory abnormalities, decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.1
Please read the full prescribing information for LIFYORLI.
Media Contact: Benito Fernandez, Chief Commercial Officer
516-640-1332
References:
1LIFYORLI™ (relacorilant) [Package Insert]. Redwood City, CA. Corcept Therapeutics. 2026.
2Olawaiye, A, Gladieff, L, et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer. JCO 43. (2025). DOI:10.1200/JCO.2025.43.17_suppl.LBA5507